5 stories found
Several biotech companies reported positive clinical trial data, including Pharvaris' drug for hereditary angioedema, Roivant's mosliciguat, and Genflow's SLAB trial, boosting their stock prices.
For Pharvaris investors, the recent sale by a director is considered less significant than the company's upcoming developments.
Pharvaris released its financial results for the second quarter of the year.
DynaResource has announced its financial results for the fourth quarter.
The Chief Medical Officer of Pharvaris sold 14,000 shares of the company's stock, totaling $427,000. This transaction represents an insider sale of company equity.